Literature DB >> 17602619

Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology.

Andrew S Felts, Chuan Ji, Jennifer B Stafford, Brenda C Crews, Philip J Kingsley, Carol A Rouzer, Mary Kay Washington, Kotha Subbaramaiah, Brianna S Siegel, Shiu M Young, Andrew J Dannenberg, Lawrence J Marnett.   

Abstract

Cyclooxygenases (COX) have been implicated in the etiology of a number of diseases, but defining the precise contribution of COXs to these diseases is challenging. Potent COX inhibitors exist, but they display off-target effects. 2'-Desmethyl derivatives of indomethacin and sulindac sulfide were synthesized that demonstrated reduced COX inhibitory activity but were inducers of peroxisome proliferator-activated receptor gamma-dependent transcription, adipocyte differentiation, or apoptosis of colon cancer cell lines. 2'-Desmethylindomethacin demonstrated gastrointestinal toxicity lower than that of indomethacin in C57BL6 mice, highlighting the importance of COX activity in maintaining gastrointestinal homeostasis and establishing that COX inhibition contributes to gastrointestinal toxicity by nonsteroidal antiinflammatory drugs. These compounds serve as useful probes of COX-dependent biology and may represent leads for antidiabetic and anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602619     DOI: 10.1021/cb700077z

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  11 in total

1.  The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives.

Authors:  Matthew J Walters; Anna L Blobaum; Philip J Kingsley; Andrew S Felts; Gary A Sulikowski; Lawrence J Marnett
Journal:  Bioorg Med Chem Lett       Date:  2009-04-23       Impact factor: 2.823

2.  The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac.

Authors:  Xingya Wang; Philip J Kingsley; Larry J Marnett; Thomas E Eling
Journal:  Cancer Prev Res (Phila)       Date:  2011-01

3.  The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites.

Authors:  Tsuyoshi Waku; Takuma Shiraki; Takuji Oyama; Kanako Maebara; Rinna Nakamori; Kosuke Morikawa
Journal:  EMBO J       Date:  2010-08-17       Impact factor: 11.598

4.  Synthesis of oligo(ethylene glycol) substituted phosphatidylcholines: secretory PLA2-targeted precursors of NSAID prodrugs.

Authors:  Renato Rosseto; Joseph Hajdu
Journal:  Chem Phys Lipids       Date:  2010-01       Impact factor: 3.329

5.  Straightforward protocol for the efficient synthesis of varied N(1)-acylated (aza)indole 2-/3-alkanoic acids and esters: optimization and scale-up.

Authors:  Andy J Liedtke; Kwangho Kim; Donald F Stec; Gary A Sulikowski; Lawrence J Marnett
Journal:  Tetrahedron       Date:  2012-12-02       Impact factor: 2.457

6.  Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

Authors:  Chung-Wei Lee; Barry Rickman; Arlin B Rogers; Sureshkumar Muthupalani; Shigeo Takaishi; Peiying Yang; Timothy C Wang; James G Fox
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

7.  Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.

Authors:  Andy J Liedtke; Adegoke O Adeniji; Mo Chen; Michael C Byrns; Yi Jin; David W Christianson; Lawrence J Marnett; Trevor M Penning
Journal:  J Med Chem       Date:  2013-03-13       Impact factor: 7.446

8.  Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.

Authors:  Andy J Liedtke; Brenda C Crews; Cristina M Daniel; Anna L Blobaum; Philip J Kingsley; Kebreab Ghebreselasie; Lawrence J Marnett
Journal:  J Med Chem       Date:  2012-02-14       Impact factor: 7.446

9.  Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition.

Authors:  Andrew S Felts; Brianna S Siegel; Shiu M Young; Christopher W Moth; Terry P Lybrand; Andrew J Dannenberg; Lawrence J Marnett; Kotha Subbaramaiah
Journal:  J Med Chem       Date:  2008-07-30       Impact factor: 7.446

10.  Current understanding of the role of PPARγ in gastrointestinal cancers.

Authors:  Bing Zou; Liang Qiao; Benjamin C Y Wong
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.